SLC2A1 and neoplasm: Significant overexpression of SLC2A1 was identified in LUAD patients with T3 and T4 tumor stages, N1 nodal involvement, and stage III and IV disease (P < 0.01), whereas no correlation with the M stage and residual tumor was observed (P > 0.05) (S3, A–S3D Fig).